Bank of New York Mellon’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $69.1M | Buy |
304,486
+8,573
| +3% | +$1.53M | 0.01% | 864 |
|
|
2026
Q1 | $51M | Sell |
295,913
-36,321
| -11% | -$6.73M | 0.01% | 983 |
|
|
2025
Q4 | $66.3M | Sell |
332,234
-82,891
| -20% | -$15M | 0.01% | 844 |
|
|
2025
Q3 | $65M | Buy |
415,125
+29,076
| +8% | +$4.62M | 0.01% | 853 |
|
|
2025
Q2 | $58.6M | Buy |
386,049
+40,720
| +12% | +$5.43M | 0.01% | 886 |
|
|
2025
Q1 | $52M | Sell |
345,329
-123,265
| -26% | -$20.7M | 0.01% | 946 |
|
|
2024
Q4 | $86.5M | Sell |
468,594
-8,557
| -2% | -$1.65M | 0.02% | 704 |
|
|
2024
Q3 | $94M | Sell |
477,151
-3,191
| -0.7% | -$663K | 0.02% | 674 |
|
|
2024
Q2 | $99.2M | Buy |
480,342
+96,319
| +25% | +$21.8M | 0.02% | 650 |
|
|
2024
Q1 | $104M | Sell |
384,023
-12,574
| -3% | -$3M | 0.02% | 637 |
|
|
2023
Q4 | $93.8M | Sell |
396,597
-15,856
| -4% | -$3.12M | 0.02% | 682 |
|
|
2023
Q3 | $80.8M | Buy |
412,453
+7,590
| +2% | +$1.56M | 0.02% | 722 |
|
|
2023
Q2 | $85.1M | Sell |
404,863
-11,762
| -3% | -$2.34M | 0.02% | 703 |
|
|
2023
Q1 | $84.1M | Sell |
416,625
-6,929
| -2% | -$1.57M | 0.02% | 697 |
|
|
2022
Q4 | $92.3M | Sell |
423,554
-59,172
| -12% | -$12.9M | 0.02% | 651 |
|
|
2022
Q3 | $95M | Sell |
482,726
-62,369
| -11% | -$13.5M | 0.02% | 619 |
|
|
2022
Q2 | $117M | Buy |
545,095
+19,329
| +4% | +$4.72M | 0.03% | 554 |
|
|
2022
Q1 | $149M | Buy |
525,766
+621
| +0.1% | +$191K | 0.03% | 510 |
|
|
2021
Q4 | $198M | Buy |
525,145
+54,853
| +12% | +$21.3M | 0.04% | 438 |
|
|
2021
Q3 | $194M | Buy |
470,292
+45,418
| +11% | +$18.9M | 0.04% | 414 |
|
|
2021
Q2 | $157M | Sell |
424,874
-88,777
| -17% | -$29.6M | 0.03% | 496 |
|
|
2021
Q1 | $149M | Sell |
513,651
-35,926
| -7% | -$9.99M | 0.03% | 517 |
|
|
2020
Q4 | $137M | Sell |
549,577
-2,431
| -0.4% | -$579K | 0.03% | 507 |
|
|
2020
Q3 | $125M | Sell |
552,008
-20,610
| -4% | -$4.28M | 0.03% | 484 |
|
|
2020
Q2 | $99.8M | Sell |
572,618
-17,004
| -3% | -$2.71M | 0.03% | 539 |
|
|
2020
Q1 | $74.4M | Sell |
589,622
-225,915
| -28% | -$33.9M | 0.02% | 575 |
|
|
2019
Q4 | $125M | Sell |
815,537
-144,992
| -15% | -$20.1M | 0.03% | 503 |
|
|
2019
Q3 | $127M | Sell |
960,529
-17,654
| -2% | -$2.37M | 0.03% | 465 |
|
|
2019
Q2 | $139M | Buy |
978,183
+323,625
| +49% | +$43.9M | 0.04% | 456 |
|
|
2019
Q1 | $95.1M | Sell |
654,558
-14,770
| -2% | -$1.94M | 0.03% | 605 |
|
|
2018
Q4 | $75.8M | Sell |
669,328
-85,753
| -11% | -$10.7M | 0.02% | 658 |
|
|
2018
Q3 | $102M | Sell |
755,081
-29,268
| -4% | -$3.61M | 0.03% | 613 |
|
|
2018
Q2 | $88.1M | Sell |
784,349
-32,702
| -4% | -$3.54M | 0.02% | 658 |
|
|
2018
Q1 | $87.2M | Buy |
817,051
+14,391
| +2% | +$1.55M | 0.02% | 666 |
|
|
2017
Q4 | $87.9M | Sell |
802,660
-10,330
| -1% | -$1.12M | 0.02% | 702 |
|
|
2017
Q3 | $87.8M | Sell |
812,990
-27,653
| -3% | -$2.84M | 0.02% | 671 |
|
|
2017
Q2 | $85M | Sell |
840,643
-99,837
| -11% | -$9.19M | 0.02% | 662 |
|
|
2017
Q1 | $84.6M | Sell |
940,480
-11,339
| -1% | -$963K | 0.02% | 663 |
|
|
2016
Q4 | $72.5M | Buy |
951,819
+11,106
| +1% | +$843K | 0.02% | 725 |
|
|
2016
Q3 | $78.4M | Sell |
940,713
-16,247
| -2% | -$1.36M | 0.02% | 651 |
|
|
2016
Q2 | $78.9M | Sell |
956,960
-4,090
| -0.4% | -$337K | 0.02% | 631 |
|
|
2016
Q1 | $73M | Buy |
961,050
+11,688
| +1% | +$865K | 0.02% | 692 |
|
|
2015
Q4 | $76.3M | Buy |
949,362
+29,808
| +3% | +$2.15M | 0.02% | 657 |
|
|
2015
Q3 | $58.4M | Buy |
919,554
+41,815
| +5% | +$3M | 0.02% | 771 |
|
|
2015
Q2 | $61.7M | Buy |
877,739
+8,814
| +1% | +$652K | 0.02% | 788 |
|
|
2015
Q1 | $68.9M | Buy |
868,925
+6,865
| +0.8% | +$506K | 0.02% | 753 |
|
|
2014
Q4 | $54.9M | Buy |
862,060
+14,587
| +2% | +$914K | 0.01% | 844 |
|
|
2014
Q3 | $50.6M | Buy |
847,473
+22,972
| +3% | +$1.31M | 0.01% | 865 |
|
|
2014
Q2 | $44.1M | Sell |
824,501
-81,632
| -9% | -$4.48M | 0.01% | 981 |
|
|
2014
Q1 | $54.7M | Sell |
906,133
-59,265
| -6% | -$3.45M | 0.01% | 837 |
|
|
2013
Q4 | $51.2M | Sell |
965,398
-24,148
| -2% | -$1.21M | 0.01% | 873 |
|
|
2013
Q3 | $45.8M | Sell |
989,546
-448,008
| -31% | -$20.6M | 0.01% | 913 |
|
|
2013
Q2 | $59M | Buy |
+1,437,554
| New | +$61.6M | 0.02% | 733 |
|
Other funds holding CRL
AI
Bank of New York Mellon's CRL Position: Q2 2026 in Review
Bank of New York Mellon increased its Charles River Laboratories (CRL) stake by 2.9% in Q2 2026, buying an estimated $1.53M and bringing the position to 304,486 shares worth $69.1M. The position accounts for 0.01% of the portfolio, ranked #864.
Bank of New York Mellon first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. The position peaked at $198M in Q4 2021. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Bank of New York Mellon held 304,486 shares of Charles River Laboratories worth $69.1M as of Q2 2026.
- Bank of New York Mellon bought 8,573 Charles River Laboratories shares in Q2 2026, an estimated $1.53M.
- Charles River Laboratories made up 0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #864 holding.
- Bank of New York Mellon first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
- Bank of New York Mellon's Charles River Laboratories position peaked at $198M in Q4 2021.
- 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.